These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27254305)

  • 1. Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma.
    Agarwal N; Shuch B; Pal SK
    JAMA Oncol; 2016 Oct; 2(10):1273-1274. PubMed ID: 27254305
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
    J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
    Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
    J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
    Alhalabi O; Karam JA; Tannir NM
    Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.
    Hong X; Li F; Tang K; Pang S; Lin G; Li S; Bao J; Tan W
    Int Urol Nephrol; 2016 Jun; 48(6):967-75. PubMed ID: 26861063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization.
    Psutka SP; Kim SP; Gross CP; Van Houten H; Thompson RH; Abouassaly R; Weight C; Boorjian SA; Leibovich BC; Shah ND
    Urology; 2015 Feb; 85(2):442-50. PubMed ID: 25623717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cytoreductive surgery in the era of targeted agents.
    Noe A; Stewart GD; Bex A
    Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of surgery and systemic therapy in the management of metastatic renal cancer.
    Thomas AA; Rini BI; Campbell SC
    Curr Urol Rep; 2009 Jan; 10(1):35-41. PubMed ID: 19116094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is cytoreductive nephrectomy relevant in the immunotherapy era?
    Singla N; Ghandour RA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.
    Shapiro DD; Abel EJ
    Curr Opin Urol; 2019 Sep; 29(5):513-520. PubMed ID: 31305274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment.
    Kübler HR
    Urology; 2015 Feb; 85(2):450-1. PubMed ID: 25623718
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
    Bigot P; Lebdai S; Azzouzi AR
    Int J Urol; 2015 Aug; 22(8):740-1. PubMed ID: 26012629
    [No Abstract]   [Full Text] [Related]  

  • 16. PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
    Jiang W; Wang D; Liu X; Zheng W; Wen L; Shi H; Zhang H; Zhou A; Li C; Ma J; Zheng S; Shou J
    Urol Oncol; 2021 Jan; 39(1):78.e9-78.e16. PubMed ID: 32988712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
    Ishiyama Y; Urabe F
    Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
    Tatsugami K; Shinohara N; Kondo T; Yamasaki T; Eto M; Tsushima T; Terachi T; Naito S;
    Int J Urol; 2015 Aug; 22(8):736-40. PubMed ID: 25988793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
    Shinohara N; Abe T
    Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
    Mano R; Gopal N; Hakimi AA
    Curr Opin Urol; 2019 Sep; 29(5):531-539. PubMed ID: 31313716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.